Top Markets
Coin of the day
IMV Inc. IMV Inc.

IMV Inc.

IMV
Rang in Aktien #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Aktienkurs
$0.82959892
Zuletzt synchronisiert: 2023-05-23
Marktkapitalisierung
$4.16M
Veränderung (1 Tag)
-0.04%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel IMV Inc. (IMV)

Kategorie

Aktien-Split-Historie für IMV Inc. (IMV)
Die Aktie IMV Inc. (Symbol: IMV) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 16, 2026 statt.
Eine IMV-Aktie, die vor dem Aug 16, 2026 gekauft wurde, entspricht heute 0 IMV-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE